Overview
The Stop TB Partnership Working Group on New Drugs’ Annual Meeting has proven valuable as a neutral forum to bring together those working in research and development to get a full understanding of the progress, challenges, and critical issues to developing TB treatment.
Speakers
Melvin Spigelman
TB Alliance, WGND
Barbara Laughon
NIH/NIAID, WGND
Zaid Tanvir
TB Alliance, WGND
Andrew Nunn
Clinical Trials Unit, MRC
Gavin Churchyard
AIDS Clinical Trials Group
June Kim
Qurient
Julia Dreisbach
University of Munich
Norbert Heinrich
University of Munich
Tine DeMarez
Janssen
Robert Bates
GlaxoSmithKline
Charles Wells
Gates Medical Research Institute
Steve Berthel
TB Drug Accelerator
Francesca Conradie
Nicholas Paton
SPRINT-TB
Andrew Vernon
TB Trials Consortium (CDC)
Morounfolu Olugbosi
TB Alliance
Marc Destito
Otsuka
Brendan Crowley
Merck
Daniel Frank
NIAID, NIH
Thomas Manning
Robert Wallis
The Aurum Institute
Meeting Recap
The 2020 WGND Annual Meeting took place on Monday, October 19th at 9AM -12PM EDT. During the meeting, updates were provided by representatives from pharmaceutical, government agencies, research organizations, non-profits, academia, and others involved in TB research and development.
Presentations and Q&A from the meeting are posted below.
- TB Drug Development Year-in-ReviewBarbara Laughonhttps://www.newtbdrugs.org/sites/default/files/meetings/files/01_Barbara%20Laughon_Year-in-Review%20Revised%20Nov%208.pdfWGND UpdatesZaid Tanvirhttps://www.newtbdrugs.org/sites/default/files/meetings/files/02_Zaid%20Tanvir_WGND%20Update.pdfSTREAM2Andrew Nunnhttps://www.newtbdrugs.org/sites/default/files/meetings/files/03__Andrew%20Nunn_STREAM.pdfAIDS Clinical Trials GroupGavin Churchyardhttps://www.newtbdrugs.org/sites/default/files/meetings/files/04_Gavin%20Churchyard_ACTG.pdfQurient, Inc.June Kimhttps://www.newtbdrugs.org/sites/default/files/meetings/files/05_June%20Kim_Qurient_Telacebec_.pdfUniversity of Munich / PanACEANorbert HeinrichJulia Dreisbachhttps://www.newtbdrugs.org/sites/default/files/meetings/files/06_Julia%20Dreisbach%20%26%20Norbert%20Heinrich_PanACEA%20LMU.pdfJanssenTine DeMarezhttps://www.newtbdrugs.org/sites/default/files/meetings/files/07_Tine%20De%20Marez_Janssen.pdfGlaxoSmithKlineRobert Bateshttps://www.newtbdrugs.org/sites/default/files/meetings/files/08_Rob%20Bates_GSK.pdfBEAT TuberculosisFrancesca Conradiehttps://www.newtbdrugs.org/sites/default/files/meetings/files/11_Francesca%20Conradie_BEAT%20TB.pdfTB Drug AcceleratorSteve Berthelhttps://www.newtbdrugs.org/sites/default/files/meetings/files/10_Steve%20Berthel_TBDA.pdfGates Medical Research InstituteCharles Wellshttps://www.newtbdrugs.org/sites/default/files/meetings/files/09_Charles%20Wells_GMRI.pdfSPRINT-TBNicholas Patonhttps://www.newtbdrugs.org/sites/default/files/meetings/files/12_Nick%20Paton_TRUNCATE-TB.pdfCenters for Disease Control/ TB Trials ConsortiumAndrew Vernonhttps://www.newtbdrugs.org/sites/default/files/meetings/files/13_Andrew%20Vernon_CDC%20TBTC.pdfTB AllianceMorounfolu Olugbosihttps://www.newtbdrugs.org/sites/default/files/meetings/files/14_Folu%20Olugbosi_TB%20Alliance_0.pdfOtsukaMarc Destitohttps://www.newtbdrugs.org/sites/default/files/meetings/files/15_Marc%20Destito_Otsuka.pdfMerckBrendan CrowleyDAIDS/NIAID, NIHDaniel Frankhttps://www.newtbdrugs.org/sites/default/files/meetings/files/17_Daniel%20Frank_DAIDS_NIAID_NIH.pdfValdosta State UniversityThomas Manninghttps://www.newtbdrugs.org/sites/default/files/meetings/files/18_Thomas%20Manning_Valdosta%20University.pdfAurum InstituteRobert Wallishttps://www.newtbdrugs.org/sites/default/files/meetings/files/19_Bob%20Wallis_Aurum.pdf
Downloads